Improving treatment for blood cancers in ovarian cancer survivors
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
This study is looking for better treatment options for ovarian cancer patients who develop serious blood disorders after using certain medications, especially those with a specific gene mutation that makes standard treatments less effective, so they can live longer and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11082268 on NIH RePORTER |
What this research studies
This research focuses on therapy-related myeloid neoplasms (tMNs), which are serious blood disorders that can develop in ovarian cancer patients who have undergone treatment with PARP inhibitors. The study aims to explore new therapeutic approaches to improve outcomes for these patients, particularly those with mutations in the TP53 gene, which are associated with poor responses to standard chemotherapy. By investigating the use of replication checkpoint modulators, the research seeks to find more effective treatments that could extend survival and improve quality of life for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer survivors who have developed therapy-related myeloid neoplasms after receiving PARP inhibitor treatment.
Not a fit: Patients who have not received PARP inhibitors or who do not have therapy-related myeloid neoplasms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer survivors who develop severe blood cancers, potentially improving their survival rates.
How similar studies have performed: Previous research has shown promising results in treating similar blood cancers, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kaufmann, Scott H — Mayo Clinic Rochester
- Study coordinator: Kaufmann, Scott H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.